{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:44:49Z","timestamp":1778636689350,"version":"3.51.4"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>The novel coronavirus originated in December 2019 in Hubei, China. This contagious disease named as COVID-19 resulted in a massive expansion within 6\u00a0months by spreading to more than 213 countries. Despite the availability of antiviral drugs for the treatment of various viral infections, it was concluded by the WHO that there is no medicine to treat novel CoV, SARS-CoV-2. It has been confirmed that SARS-COV-2 is the most highly virulent human coronavirus and occupies the third position following SARS and MERS with the highest mortality rate. The genetic assembly of SARS-CoV-2 is segmented into structural and non-structural proteins, of which two-thirds of the viral genome encodes non-structural proteins and the remaining genome encodes structural proteins. The most predominant structural proteins that make up SARS-CoV-2 include spike surface glycoproteins (S), membrane proteins (M), envelope proteins (E), and nucleocapsid proteins (N). This review will focus on one of the four major structural proteins in the CoV assembly, the spike, which is involved in host cell recognition and the fusion process. The monomer disintegrates into S1 and S2 subunits with the S1 domain necessitating binding of the virus to its host cell receptor and the S2 domain mediating the viral fusion. On viral infection by the host, the S protein is further cleaved by the protease enzyme to two major subdomains S1\/S2. Spike is proven to be an interesting target for developing vaccines and in particular, the RBD-single chain dimer has shown initial success. The availability of small molecules and peptidic inhibitors for host cell receptors is briefly discussed. The development of new molecules and therapeutic druggable targets for SARS-CoV-2 is of global importance. Attacking the virus employing multiple targets and strategies is the best way to inhibit the virus. This article will appeal to researchers in understanding the structural and biological aspects of the S protein in the field of drug design and discovery.<\/jats:p>","DOI":"10.3389\/fmolb.2021.637550","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T06:00:38Z","timestamp":1615874438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["An Overview of Spike Surface Glycoprotein in Severe Acute Respiratory Syndrome\u2013Coronavirus"],"prefix":"10.3389","volume":"8","author":[{"given":"Muthu Kumaradoss","family":"Kathiravan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srimathi","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vigneshwaran","family":"Namasivayam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilkumar","family":"Palaniappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1128\/JVI.00998-13","article-title":"Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms","volume":"87","author":"Adedeji","year":"2013","journal-title":"J. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1177932220965505","DOI":"10.1177\/1177932220965505","article-title":"Targeting the GRP78-dependant SARS-CoV-2 cell entry by peptides and small molecules","volume":"14","author":"Allam","year":"2020","journal-title":"Bioinform Biol. Insights"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jsps.2020.08.024","article-title":"Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective","volume":"28","author":"Alnefaie","year":"2020","journal-title":"Saudi Pharm. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2217\/fvl-2020-0129","article-title":"Genetic and pathogenic characterization of SARS-CoV-2: a review","volume":"15","author":"Bahrami","year":"2020","journal-title":"Future Virol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1073\/pnas.0400576101","article-title":"Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides","volume":"101","author":"Bosch","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/bcpt.13533","article-title":"Camostat mesylate against SARS\u2010CoV\u20102 and COVID\u201019-Rationale, dosing and safety","volume":"128","author":"Breining","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"9279","DOI":"10.1128\/JVI.00659-06","article-title":"Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein","volume":"80","author":"Chan","year":"2006","journal-title":"J. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerging Microbes & Infections"},{"key":"B9","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1038\/s41467-020-18387-8","article-title":"Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain","volume":"11","author":"Chi","year":"2020","journal-title":"Nat. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"10543","DOI":"10.1128\/JVI.78.19.10543-10555.2004","article-title":"Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway","volume":"78","author":"Chu","year":"2004","journal-title":"J. Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J. Virol."},{"key":"B12","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1055\/s-0040-1721319","article-title":"Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin","volume":"120","author":"Courtney","year":"2020","journal-title":"Thromb. Haemost"},{"key":"B13","doi-asserted-by":"publisher","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/molecules25030698","article-title":"A review of small molecule inhibitors and functional probes of human cathepsin L","volume":"25","author":"Dana","year":"2020","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/d41587-020-00016-w","article-title":"Coronavirus vaccine developers wary of errant antibodies","author":"Garber","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13059-020-02191-0","article-title":"Potentially adaptive SARS-CoV-2 mutations discovered with novel spatiotemporal and explainable AI models","volume":"21","author":"Garvin","year":"2020","journal-title":"Genome Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/v4113044","article-title":"Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies","volume":"4","author":"Geller","year":"2012","journal-title":"Viruses"},{"key":"B21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2014an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil. Med. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jinf.2020.06.017","article-title":"The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection","volume":"81","author":"Ha","year":"2020","journal-title":"J. Infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.virol.2006.01.029","article-title":"Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor","volume":"350","author":"Han","year":"2006","journal-title":"Virology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1021\/acsptsci.0c00161","article-title":"Targeting ACE2-RBD interaction as a platform for COVID-19 therapeutics: development and drug-repurposing screen of an AlphaLISA proximity assay","volume":"3","author":"Hanson","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.antiviral.2006.04.014","article-title":"Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction","volume":"74","author":"Ho","year":"2007","journal-title":"Antivir. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2005.10.005","article-title":"Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction","volume":"69","author":"Ho","year":"2006","journal-title":"Antivir. Res."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.05.237651","article-title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity","author":"Hoffmann","year":"","journal-title":"BioRxiv"},{"key":"B29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","volume":"78","author":"Hoffmann","year":"","journal-title":"Mol. Cel"},{"key":"B30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin"},{"key":"B32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","article-title":"Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor","volume":"44","author":"Huentelman","year":"2004","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jinf.2020.02.026","article-title":"COVID-19 spike-host cell receptor GRP78 binding site prediction","volume":"80","author":"Ibrahim","year":"2020","journal-title":"J. Infect."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1128\/JVI.00253-07","article-title":"Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted","volume":"81","author":"Inoue","year":"2007","journal-title":"J. Virol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1586\/erv.12.126","article-title":"Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome","volume":"11","author":"Jiang","year":"2012","journal-title":"Expert Rev. Vaccin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerging Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.it.2020.04.008","article-title":"Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses: (trends in immunology 41, 355-359; 2020)","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1128\/JVI.75.4.1958-1967.2001","article-title":"Entry of human parechovirus 1","volume":"75","author":"Joki-Korpela","year":"2001","journal-title":"J. Virol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.chembiol.2004.07.013","article-title":"Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics","volume":"11","author":"Kao","year":"2004","journal-title":"Chem. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2020.05.009","article-title":"Silico computational screening of Kabasura kudineer\u2014official Siddha formulation and JACOM against SARS-CoV-2 spike protein","author":"Kiran","year":"2020","journal-title":"J. Ayurveda Integr. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"B46","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13337-020-00632-9","article-title":"SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations","volume":"31","author":"Krishnamoorthy","year":"2020","journal-title":"VirusDis."},{"key":"B48","first-page":"209","article-title":"Influence of chlorpromazine on the replication of influenza virus in chick embryo cells","volume":"26","author":"Krizanov\u00e1","year":"1982","journal-title":"Acta virologica"},{"key":"B49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.antiviral.2011.02.003","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB\/c mouse model by stinging nettle lectin, Urtica dioica agglutinin","volume":"90","author":"Kumaki","year":"2011","journal-title":"Antivir. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B52","doi-asserted-by":"publisher","first-page":"100048","DOI":"10.1016\/j.medntd.2020.100048","article-title":"Spike protein-based epitopes predicted against SARS-CoV-2 through literature mining","volume":"8","author":"Li","year":"2020","journal-title":"Med. Nov Technol. Devices"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.10.087288","article-title":"SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner","author":"Liu","year":"2020","journal-title":"BioRxiv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e123158","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI insight"},{"key":"B55","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1128\/AAC.03977-14","article-title":"Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry","volume":"59","author":"Liu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/ncomms4067","article-title":"Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor","volume":"5","author":"Lu","year":"2014","journal-title":"Nat. Commun."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e1004166","DOI":"10.1371\/journal.ppat.1004166","article-title":"Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus","volume":"10","author":"Lundin","year":"2014","journal-title":"Plos Pathog."},{"key":"B59","doi-asserted-by":"publisher","first-page":"m1166","DOI":"10.1136\/bmj.m1166","article-title":"Covid-19: six million doses of hydroxychloroquine donated to US despite lack of evidence","volume":"368","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"B60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13337-020-00598-8","article-title":"Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor","volume":"31","author":"Maurya","year":"2020","journal-title":"Virusdisease"},{"key":"B61","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(20)31180-6","article-title":"RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","volume":"22","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nm.4131","article-title":"A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation","volume":"22","author":"Modjarrad","year":"2016","journal-title":"Nat. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1099\/vir.0.18883-0","article-title":"Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine","volume":"84","author":"Nawa","year":"2003","journal-title":"J. Gen. Virol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1128\/JVI.02322-09","article-title":"Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae","volume":"84","author":"O\u2019Keefe","year":"2010","journal-title":"J. Virol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"B68","doi-asserted-by":"publisher","first-page":"e7423","DOI":"10.7759\/cureus.7423","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update","volume":"12","author":"Pal","year":"2020","journal-title":"Cureus"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1796811","article-title":"Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development","author":"Pandey","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12482435.v1","article-title":"Drug repurposing for covid-19: discovery of potential small-molecule inhibitors of spike protein-ACE2 receptor interaction through virtual screening and consensus scoring","author":"Patil","year":"2020","journal-title":"ChemRxiv"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/jclinpath-2020-206658","article-title":"Gene of the month: the 2019-nCoV\/SARS-CoV-2 novel coronavirus spike protein","volume":"73","author":"Pillay","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1779129","article-title":"In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2","author":"Prasanth","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1776639","article-title":"Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms","author":"Quimque","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B75","doi-asserted-by":"publisher","first-page":"114227","DOI":"10.1016\/j.bcp.2020.114227","article-title":"AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication","volume":"182","author":"Rayner","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"103670","DOI":"10.1016\/j.compbiomed.2020.103670","article-title":"Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus","volume":"119","author":"Robson","year":"2020","journal-title":"Comput. Biol. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/s1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B79","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1124\/mol.110.064261","article-title":"A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells","volume":"78","author":"Shah","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J. Virol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1073\/pnas.0505577102","article-title":"Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry","volume":"102","author":"Simmons","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1762741","article-title":"An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets","author":"Sinha","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B83","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1099\/jgv.0.001047","article-title":"Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors","volume":"99","author":"Sisk","year":"2018","journal-title":"J. Gen. Virol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1007236","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"Plos Pathog."},{"key":"B85","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","article-title":"Is COVID-19 receiving ADE from other coronaviruses?","volume":"22","author":"Tetro","year":"2020","journal-title":"Microbes Infect."},{"key":"B86","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B87","doi-asserted-by":"publisher","first-page":"17996","DOI":"10.1074\/jbc.M311191200","article-title":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis","volume":"279","author":"Towler","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cyto.a.24047","article-title":"Dengue fever, covid \u201019 ( SARS\u2010CoV\u20102), and antibody\u2010dependent enhancement (ADE): a perspective","volume":"97","author":"Ulrich","year":"2020","journal-title":"Cytometry"},{"key":"B89","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.cell.2018.12.028","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"176","author":"Walls","year":"2019","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang C.","year":"2020","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.14.988345","article-title":"SARS-CoV-2 invades host cells via a novel route: CD147-spike protein","author":"Wang","year":"2020","journal-title":"BioRxiv"},{"key":"B95","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43556-020-00008-x","article-title":"A promising vaccine candidate against COVID-19","volume":"8","author":"Wang","year":"2020","journal-title":"Mol. Biomed."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cel Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.1073\/pnas.1405889111","article-title":"Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus","volume":"111","author":"Yang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"B103","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"11334","DOI":"10.1128\/JVI.78.20.11334-11339.2004","article-title":"Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells","volume":"78","author":"Yi","year":"2004","journal-title":"J. Virol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","article-title":"Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant","volume":"183","author":"Yurkovetskiy","year":"2020","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","volume":"55","author":"Zhai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.05.935387","article-title":"Teicoplanin potently blocks the cell entry of 2019-nCoV","author":"Zhang","year":"2020","journal-title":"BioRxiv"},{"key":"B108","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/1743-422X-10-266","article-title":"A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV","volume":"10","author":"Zhao","year":"2013","journal-title":"Virol. J."},{"key":"B109","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B110","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"B111","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antivir. Res."},{"key":"B112","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/v11010060","article-title":"Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain","volume":"11","author":"Zhou","year":"2019","journal-title":"Viruses"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.637550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T10:11:27Z","timestamp":1617790287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.637550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":112,"alternative-id":["10.3389\/fmolb.2021.637550"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.637550","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"article-number":"637550"}}